Fusion Pharmaceuticals (FUSN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Targeted Radiotherapeuticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-15. ClinicalTrials.gov
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 3 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 15, 2026 · ingested Nov 15, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 0 | Unavailable Coverage unavailable: no DilutionWatch score for this company |
DilutionWatch score (derived from SEC filings) |
| Short interest | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
FINRA short interest |
| Publications | 5 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 17, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 37.2/100 (grade D):
- Clinical trials: signal score 0.38, weight used 98%, 36.8 points
- Publications: signal score 0.25, weight used 2%, 0.5 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent Publications
- Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. — Cancer 2025 Aug 1 PMID 40753466
- Targeting TRPML3 inhibits proliferation and invasion, and enhances doxorubicin sensitivity by disrupting lysosomal acidification and mitochondrial function in triple-negative breast cancer. — Biochim Biophys Acta Mol Cell Res 2025 Aug PMID 40348344
- CDC40 suppression induces CDCA5 splicing defects and anti-proliferative effects in lung cancer cells. — Sci Rep 2025 Jan 2 PMID 39747150
- VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. — JAMA 2023 Apr 25 PMID 37060545
- Clock at the Core of Cancer Development. — Biology (Basel) 2021 Feb 14 PMID 33672910
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Fusion Pharmaceuticals.
Full FUSN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.